Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Brazilian cardiovascular researcher receives Georg Forster Research Award

The cardiovascular researcher Professor Robson Augusto Souza dos Santos of the Federal University of Minas Gerais in Belo Horizonte, Brazil, has been awarded the Georg Forster Research Award of the Alexander von Humboldt Foundation.

28 Jul 2015

New review article explains link between PTSD and increased cardiovascular disease risk

A growing number of patient studies show that people who suffered post-traumatic stress disorder (PTSD) are at a higher risk of developing cardiovascular diseases, including stroke and heart attack. A new review article in American Journal of Physiology—Regulatory, Integrative and Comparative Physiology examines the recent scientific literature to explain how the two are linked.

15 Jul 2015

New drug patiromer could improve potassium levels of patients with diabetic kidney disease

Among patients with diabetic kidney disease and hyperkalemia (elevated potassium levels in the blood), a potentially life-threatening condition, those who received the new drug patiromer, twice daily for four weeks, had significant decreases in potassium levels which lasted through one year, according to a study in the July 14 issue of JAMA.

15 Jul 2015

FDA approves new heart failure drug

A new drug called Entresto has been approved by the U.S Food and Drug Administration (FDA) for the treatment of heart failure.

9 Jul 2015

Novartis announces FDA approval of Entresto to reduce risk of cardiovascular death, heart failure hospitalization

Novartis announced today that the US Food and Drug Administration has approved Entresto™ tablets, previously known as LCZ696, to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure and reduced ejection fraction.

8 Jul 2015

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.

29 Jun 2015

Generic heart disease drugs show promise in patients affected by Ebola virus

Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology.

23 Jun 2015

New study predicts outcomes of CV patients using polypill intervention

A new study published in the journal BMJ Open (May 2015) has demonstrated that the improved treatment adherence achievable using a fixed-dose combination polypill (atorvastatin, ramipril and low-dose aspirin) to prevent recurring myocardial infarction, can avoid up to 15% more fatal and non-fatal CV events, conferring potential savings to healthcare systems.

19 Jun 2015

Adding high salt to high-fat diet prevents weight gain in mice

In a study that seems to defy conventional dietary wisdom, University of Iowa scientists have found that adding high salt to a high-fat diet actually prevents weight gain in mice.

11 Jun 2015

Researchers discover genetic mutation responsible for thoracic aortic aneurysm and dissection

Thoracic aortic aneurysm and dissection (TAAD), an enlargement or tearing of the walls of the aorta in the chest, is, together with abdominal aortic aneurysms, responsible for about 2% of all deaths in Western countries. The aorta is the largest artery in the body, and carries blood from the heart. About one out of every five patients with TAAD has a family member with the same disorder, therefore indicating a genetic cause.

8 Jun 2015

Withholding ARBs for longer than two days after surgery significantly increases risk of postoperative death

Withholding angiotensin receptor blockers (ARBs) for longer than two days after surgery is associated with a significantly increased risk of postoperative death, according to a study of more than 30,000 patients in the VA health care system by researchers at UC San Francisco and the San Francisco VA Medical Center.

5 Jun 2015

Regulus Therapeutics begins RG-012 Phase I clinical study for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21").

4 Jun 2015

Statins reduce risk of death by 67% in CABG surgery

Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications.

1 Jun 2015

Patient characteristics may guide TKI use in CML

The likelihood of complications associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia may be reduced by considering patient factors and differences in the toxicity profiles of the different drug options, a review suggests.

29 May 2015

Regular use of aspirin may slow the progression of early emphysema, new research shows

Regular use of aspirin may help slow the progression of early emphysema, according to new research presented at the 2015 American Thoracic Society International Conference.

18 May 2015

Findings could help design tailor-made drugs to treat blood pressure

One in three Americans has high blood pressure, a long-term constriction of arteries that can lead to coronary heart disease, heart failure and stroke.

25 Apr 2015

Genetic study may help identify novel targets for treatment of high blood pressure

A genetic investigation of individuals in the Framingham Heart Study may prove useful to identify novel targets for the prevention or treatment of high blood pressure. The study, which takes a close look at networks of blood pressure-related genes, is published in the journal Molecular Systems Biology.

17 Apr 2015

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB, a specialty pharma company, today announces that the NEFIGAN Trial of Nefecon for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint.

14 Apr 2015

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets.

31 Mar 2015

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia).